| Bioactivity | LQVTDSGLYRCVIYHPP (LP17) TFA is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP TFA substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP TFA can get access into brain and block TREM-1[1]. | ||||||
| Invitro | LQVTDSGLYRCVIYHPP (LP17) (1 or 10 μM; 24 h) substantially decreases mRNA levels of pro-inflammatory cytokines and chemokines after reoxygenation and remarkably attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model[1].LQVTDSGLYRCVIYHPP (LP17) (10 μM; 24 h) interacts with microglial SYK[1]. RT-PCR[1] Cell Line: | ||||||
| Name | LQVTDSGLYRCVIYHPP TFA | ||||||
| Shortening | LQVTDSGLYRCVIYHPP | ||||||
| Formula | C91H138F3N23O27S | ||||||
| Molar Mass | 2075.27 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
LQVTDSGLYRCVIYHPP TFA
CAS: F: C91H138F3N23O27S W: 2075.27
LQVTDSGLYRCVIYHPP (LP17) TFA is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYR
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.